Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23812865 | 0.90 | ALDH1A1 (0.40) | F2RL3MAPTHPGDMAPK1L3MBTL1 | |
| SCHEMBL981107 | 0.82 | NMT1 (0.34) | — | |
| SCHEMBL22954113 | 0.81 | CA1 (0.40) | F2RL3MAPTHPGDMEN1KMT2A | |
| SCHEMBL18583495 | 0.79 | CSNK2A1 (0.36) | MAPTHPGDMAPK1L3MBTL1MEN1 | |
| SCHEMBL18088629 | 0.77 | SCN4A (0.40) | MAPTHPGDL3MBTL1MEN1KMT2A | |
| SCHEMBL10359284 | 0.76 | KDM4E (0.35) | MAPTHPGDMAPK1L3MBTL1MEN1 | |
| SCHEMBL10052627 | 0.74 | KMT2A (0.33) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL18987826 | 0.74 | DRD1 (0.44) | L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL293964 | 0.72 | MEN1 (0.51) | MAPTHPGDMAPK1L3MBTL1MEN1 | |
| SCHEMBL18988000 | 0.71 | SRC (0.45) | MAPTHPGDMAPK1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204110-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2017-07-20 | — | — | US | disclosed |
| WO-2017117239-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC (US) | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204110-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | F2RL3 2432/4885MAPT 4860/4885HPGD 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.